Dapagliflozin and New-Onset Type 2 Diabetes in Patients With Chronic Kidney Disease Or Heart Failure: Pooled Analysis of the DAPA-CKD and DAPA-HF Trials

Lancet Diabetes Endocrinol 2022;10:24–34 doi.org/10.1016/

Participants with chronic kidney disease and heart failure without a reduction in HbA1c had a lower incidence of new-onset type 2 diabetes following treatment with dapagliflozin. Participants with no type 2 diabetes at baseline generally tolerated dapagliflozin.


LinkedIn